Agilent Technologies, Inc. (NYSE:A) Shares Acquired by Western Pacific Wealth Management LP

Western Pacific Wealth Management LP raised its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 59.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 758 shares of the medical research company’s stock after purchasing an additional 283 shares during the quarter. Western Pacific Wealth Management LP’s holdings in Agilent Technologies were worth $113,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of A. Vanguard Group Inc. lifted its stake in shares of Agilent Technologies by 18.2% in the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock valued at $4,348,471,000 after purchasing an additional 4,605,228 shares during the period. Massachusetts Financial Services Co. MA grew its position in Agilent Technologies by 5.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after acquiring an additional 809,149 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Agilent Technologies by 13.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after purchasing an additional 1,042,926 shares during the period. Van ECK Associates Corp increased its position in shares of Agilent Technologies by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock valued at $442,011,000 after acquiring an additional 183,716 shares during the last quarter. Finally, Impax Asset Management Group plc increased its holdings in Agilent Technologies by 8.2% in the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock valued at $396,088,000 after purchasing an additional 203,234 shares during the last quarter.

Agilent Technologies Stock Performance

Shares of A opened at $139.63 on Friday. The company has a 50-day moving average of $139.64 and a two-hundred day moving average of $138.18. The stock has a market cap of $40.12 billion, a price-to-earnings ratio of 28.97, a PEG ratio of 6.14 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. Agilent Technologies, Inc. has a one year low of $104.09 and a one year high of $155.35.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.06. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business’s revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.43 EPS. On average, equities research analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were given a dividend of $0.236 per share. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a yield of 0.68%. Agilent Technologies’s payout ratio is currently 19.50%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at $3,497,110. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,995 shares of company stock worth $1,739,510.

Analysts Set New Price Targets

A has been the topic of several recent analyst reports. Citigroup increased their price target on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. TD Cowen boosted their target price on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $151.00 price objective on shares of Agilent Technologies in a report on Monday, August 26th. UBS Group upped their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Finally, Bank of America raised their price objective on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $144.36.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.